PCN104 Cost Minimization Analysis (CMA) of Capecitabine/Cisplatin (XP) vs. 5-Fu/Cisplatin (FP) Regimens in Advanced Gastric Cancer (AGC) Treatment in the Romanian Setting
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.1205
https://www.valueinhealthjournal.com/article/S1098-3015(11)02767-7/fulltext
Title :
PCN104 Cost Minimization Analysis (CMA) of Capecitabine/Cisplatin (XP) vs. 5-Fu/Cisplatin (FP) Regimens in Advanced Gastric Cancer (AGC) Treatment in the Romanian Setting
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)02767-7&doi=10.1016/j.jval.2011.08.1205
First page :
A453
Section Title :
Cancer
Open access? :
No
Section Order :
1162